Abstract | PURPOSE: METHODS: Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m(2), twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180-200 cGy per fraction was delivered in 25-28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required. RESULTS: Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45-77 years). The median follow-up time was 11.6 months (range 1.9-49.1 months). Fifteen patients (75%) had extrahepatic cholangiocarcinoma, two patients (10%) had intrahepatic cholangiocarcinoma, and three patients (15%) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15%), and stable disease was achieved in 14 patients (70%). The overall response rate was 15%, and the disease stabilization rate was 85%. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15%), neutropenia (10%), and nausea (10%). The median progression-free survival and median overall survival were 5.9 months (range 2.2-9.5 months) and 10.8 months (range 1.1-20.4 months), respectively. CONCLUSIONS:
|
Authors | Hee Man Kim, Kyong Joo Lee, Jihye Cha, Moon Jae Chung, Seungmin Bang, Jinsil Seong, Si Young Song, Seung Woo Park |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 74
Issue 4
Pg. 861-5
(Oct 2014)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 25129491
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Drug Combinations
- S 1 (combination)
- Tegafur
- Oxonic Acid
|
Topics |
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Biliary Tract Neoplasms
(drug therapy, pathology)
- Chemoradiotherapy
(methods)
- Disease-Free Survival
- Drug Combinations
- Drug Screening Assays, Antitumor
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Oxonic Acid
(administration & dosage, adverse effects)
- Pilot Projects
- Tegafur
(administration & dosage, adverse effects)
- Treatment Outcome
|